Many young people are being mistakenly led to believe that commercial marijuana is a solution for routine anxiety. The rebound effect from using this drug often leaves anxiety and depression worse. Many adults are being deceived, by those who would profit from cannabis commercialization, that increasing access to marijuana will stem the opioid crisis.
In their April 12, 2018 op-ed, “Easing access to marijuana is not a way to solve the opioid epidemic,” published on “STAT”, Nicholas Chadi (a pediatrician who specializes in adolescent medicine at Boston Children’s Hospital) and Sharon Levy (director of the Adolescent Substance Use and Addiction Program at Boston Children’s Hospital) make a compelling cautionary case for increasing and easing access to marijuana at a population level through commercialization.
“…There is ample evidence that individuals — especially adolescents — who use marijuana have much higher rates of mood, anxiety, and psychotic disorders than their peers. The loss of motivation that we see in so many of our patients who use marijuana, its negative impact on functioning at school or at work, and its likely connection with cognitive decline are other serious and common harms.
Adolescents who use marijuana are also more likely to misuse prescription opioid medications. In our experience, nearly all of our patients with opioid addiction first used marijuana heavily.”
Here’s the full article as published at STAT:
Easing access to marijuana is not a way to solve the opioid epidemic
By NICHOLAS CHADI and SHARON LEVY APRIL 12, 2018